Printer Friendly

ANGEION REPORTS SECOND QUARTER FIGURES

 ANGEION REPORTS SECOND QUARTER FIGURES
 MINNEAPOLIS, March 11 /PRNewswire/ -- Angeion Corporation


(NASDAQ: ANGN) reported sales of $1,407,637 for the second quarter ended Jan. 31, 1991. This represents a slight increase over sales of $1,405,836 for the second quarter ended Jan. 31, 1991.
 As expected, expenses relating to Angeion's research and development for its three operating units resulted in a loss of $1,048,751, or $.11 per share, for the second quarter ended Jan. 31, 1992. This compares to a loss of $457,854, or $.05 per share, for the second quarter ended Jan. 31, 1991.
 "We continue to see the sales mix move in the right direction as the proportion of proprietary product sales to total sales increased from 24 percent to 56 percent when compared to the same quarter last year," said Wendell L. King, chairman and CEO. "As we anticipated, some impact was felt this quarter from the loss last year of a large customer. It's been a big challenge, but we've done a good job of replacing that business.
 "We are pleased with the progress of our research and development efforts this quarter," added King. "We are on an aggressive schedule for the defibrillator project. This product incorporates several innovative new concepts in implant procedure, therapy detection and delivery, and patient follow-up services. The laser catheter program is moving forward as we gather significant data in the initial phase of two separate clinical trials. We currently have 12 patents issued, including two patents on the laser catheter device, and an additional 45 pending or in process, of which 23 patents are on the implantable defibrillator."
 During the second quarter, Angeion also:
 -- Elected Donald D. Maurer to its board of directors, increasing the size of the board from seven to eight members. Maurer is founder, chairman and CEO of Empi, Inc., a medical manufacturer of noninvasive biomedical devices and accessories for electrotherapeutic applications.
 -- Raised an additional $1.9 million in net proceeds in a December financing (bringing the total net proceeds in private financing for fiscal 1992 to $3.8 million).
 Minneapolis-based Angeion Corporation is a manufacturer of cardiovascular products. Angeion's subsidiaries, AngeLase, Inc. and AngeMed, Inc., are developing products for treating various types of arrhythmias. Angeion is also traded on the Boston Stock Exchange under the symbol ANI.
 ANGEION CORPORATION
 CONDENSED STATEMENTS OF OPERATIONS
 (Unaudited)
 Three Months Ended Six Months Ended
 1/31/92 1/31/91 1/31/92 1/31/91
 Net sales $1,407,637 $1,405,836 $2,828,228 $2,658,032
 Net loss (1,048,751) (457,854) (2,104,571) (661,437)
 Loss per common share $(0.11) $(0.05) $(0.22) $(0.08)
 Weighted average number
 of shares outstanding 9,944,120 8,591,466 9,572,751 8,383,663
 CONDENSED BALANCE SHEETS
 (Unaudited)
 1/31/92 7/31/91
 Current assets $4,660,999 $3,089,862
 Property and other 2,776,063 2,255,775
 Total assets $7,437,062 $5,345,637
 Current liabilities 852,145 683,552
 Long-term debt 110,824 117,604
 Shareholders' equity 6,474,093 4,544,481
 Total liabilities & equity $7,437,062 $5,345,637
 -0- 3/11/92 R
 /CONTACT: Brenda Roth of Angeion, 612-550-9388/
 (ANGN) CO: Angeion Corporation ST: Minnesota IN: MTC SU: ERN


AL -- MN003 -- 7544 03/11/92 17:36 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 11, 1992
Words:561
Previous Article:FIRST FEDERAL CAPITAL CORP ANNOUNCES STOCK PURCHASES PURSUANT TO DIVIDEND REINVESTMENT PLAN
Next Article:UTILICORP PROJECTS LOWER FIRST QUARTER RESULTS
Topics:


Related Articles
ANGEION CORPORATION RAISES ADDITIONAL $2.1 MILLION
ANGEION REPORTS FIRST QUARTER SALES UP 13 PERCENT
ANGEION REPORTS THIRD QUARTER FIGURES
ANGEION RELEASES SECOND QUARTER FIGURES
ANGEION REPORTS THIRD QUARTER FIGURES
ANGEION REPORTS FIRST QUARTER RESULTS
Angeion and ELA Medical Collaboration Becomes Effective
Angeion Announces Three News Items: $5 Million Equity Investment; U.S. Clinical Studies of AngeFix Lead System; and European CE Mark to Market...
Angeion Transfers Certain Technology to ELA Medical In Exchange for Return of Common Stock and Warrants.
Angeion Shareholders Approve Two Transactions; Noteholders Fail to Vote.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters